oai-hal-hal-00875284v1
type: Dataset
description: International audience
issued: 2026-05-09T07:21:30.756453
language: en
modified: 2026-05-09T07:21:30.756458
title: Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
contact point: Organization
  fn: CCSD
keyword: boosted-protease-inhibitor
keyword: cohort-study
keyword: hivaids
keyword: infoeu-reposemanticsarticle
keyword: journal-articles
keyword: mesh-adult
keyword: mesh-anti-hiv-agents
keyword: mesh-antiretroviral-therapy-highly-active
keyword: mesh-benzoxazines
keyword: mesh-cohort-studies
keyword: mesh-dideoxynucleosides
keyword: mesh-female
keyword: mesh-hiv
keyword: mesh-hiv-infections
keyword: mesh-hiv-protease-inhibitors
keyword: mesh-humans
keyword: mesh-male
keyword: mesh-nevirapine
keyword: mesh-prospective-studies
keyword: mesh-treatment-outcome
keyword: mesh-viral-load
keyword: sdvmplife-sciences-q-biomicrobiology-and-parasitology
keyword: switch
keyword: virological-effectiveness
landing page: 0305-7453

https://rec.harvest-normandie.data4citizen.com/dataset/oai-hal-hal-00875284v1/resource/f451ec91-a0ca-4c62-8d40-5cab3fbabd73
type: Distribution
format: HTML
issued: 2026-05-09T07:21:30.761394
modified: 2026-05-09T07:21:30.716731
title: Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
access URL: https://hal.science/hal-00875284

test_moissonnage_selune
type: Agent